TriSalus Life Sciences (NASDAQ:TLSI) Director Mats Wahlstrom Purchases 60,000 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom purchased 60,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $2.53 per share, for a total transaction of $151,800.00. Following the completion of the acquisition, the director directly owned 147,555 shares in the company, valued at approximately $373,314.15. This trade represents a 68.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

TriSalus Life Sciences Trading Up 13.1%

Shares of NASDAQ:TLSI opened at $3.03 on Tuesday. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The business’s fifty day simple moving average is $4.14 and its 200-day simple moving average is $5.11. The company has a market capitalization of $185.77 million, a PE ratio of -2.15 and a beta of 0.56. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. As a group, equities research analysts predict that TriSalus Life Sciences, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on TLSI shares. Lake Street Capital lowered their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Canaccord Genuity Group lowered their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Weiss Ratings cut TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Hold” and an average price target of $7.50.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in the business. Empire Financial Management Company LLC grew its stake in TriSalus Life Sciences by 316.9% during the 1st quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock valued at $1,201,000 after purchasing an additional 228,248 shares during the last quarter. First Light Asset Management LLC purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at about $20,267,000. Renaissance Technologies LLC purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at about $124,000. Sei Investments Co. purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at about $275,000. Finally, Perkins Capital Management Inc. purchased a new stake in TriSalus Life Sciences during the 1st quarter valued at about $920,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.